Should I Buy PRME? PRME 2026 Analysis

Should You Buy Prime Medicine, Inc (PRME) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.540

1 Day change

10.28%

52 Week Range

6.940

Analysis Updated At

2026/04/24

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Prime Medicine Inc (PRME) is not a strong buy at the moment for a beginner investor with a long-term horizon. While there are some positive catalysts such as insider buying and a favorable analyst rating, the company's weak financial performance, lack of recent news catalysts, and neutral technical indicators suggest a wait-and-see approach is more prudent. Additionally, the pre-market price drop and lack of strong trading signals further support holding off on an immediate investment.

Technical Analysis

The MACD is slightly positive at 0.0523 and contracting, RSI is neutral at 57.616, and moving averages are converging. The stock is trading near its pivot level of 3.685 with resistance at 3.976 and support at 3.395. These indicators suggest no strong directional trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low put-call ratio for open interest indicates bullish sentiment, but the higher put-call ratio for volume suggests mixed short-term trading sentiment.

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased significantly by 18302.86% over the last month.
Oppenheimer initiated coverage with an Outperform rating and a price target of $11, citing the company's strong position in gene editing and potential for significant market share.

Neutral/Negative Catalysts

Revenue dropped by -61.61% YoY in Q4
EPS declined by -18.75% YoY, and the company remains unprofitable with a net income of -$46.08 million.
No recent news or event-driven catalysts to drive momentum.

Financial Performance

In Q4 2025, revenue dropped significantly by -61.61% YoY to $838,000. Net income improved slightly by 9.00% YoY but remains negative at -$46.08 million. EPS fell to -0.26, down -18.75% YoY. Gross margin remains at 100%. Overall, the financials indicate weak growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Oppenheimer initiated coverage with an Outperform rating and a price target of $11. The firm highlights Prime Medicine's strong position in the gene editing space, potential for multi-billion-dollar sales, and high upside potential of 100%-200% within 10-15 months based on major catalysts.

7 Analyst Rating

Wall Street analysts forecast PRME stock price to rise

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 3.210

Low

4.25

Averages

6.06

High

Current: 3.210

Low

4.25

Averages

6.06

High

Oppenheimer

Outperform

initiated

$11

AI Analysis

2026-03-12

Reason

Oppenheimer

Price Target

$11

AI Analysis

2026-03-12

initiated

Outperform

Reason

Oppenheimer initiated coverage of Prime Medicine with an Outperform rating and $11 price target.

Oppenheimer

Outperform

initiated

$11

2026-03-12

Reason

Oppenheimer

Price Target

$11

2026-03-12

initiated

Outperform

Reason

As previously reported, Oppenheimer initiated coverage of Prime Medicine with an Outperform rating and $11 price target. The firm says Prime is a key name to own in the gene editing space. The company employs prime editing, the best-in-class gene editing approach, validated via early clinical data and a BMS partnership. Prime's pipeline includes a potentially best-in-class AATD program, wherein even 10% market share yields multi-billion-dollar sales, and key opinion leaders believe gene editing could achieve about 50% market share, Oppenheimer adds. Based on peers' valuation, the firm sees potential for about 100%-200% upside following major catalysts within 10-15 months. Further, Oppenheimer believes Prime's high short interest is unrelated to fundamentals.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRME

Unlock Now

PRME Should I Buy

PRME Should I Buy

Should You Buy Prime Medicine, Inc (PRME) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch